Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Leukemia - 1 Oct 2022

Ranieri Roberta, Pianigiani Giulia, Sciabolacci Sofia, Perriello Vincenzo Maria, Marra Andrea, Cardinali Valeria, Pierangeli Sara, Milano Francesca, Gionfriddo Ilaria, Brunetti Lorenzo, Martelli Maria Paola, Falini Brunangelo

Abstract excerpt

Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is predominantly located in the nucleolus and exerts multiple functions, including regulation of centrosome duplication, ribosome biogenesis and export, histone assembly, maintenance of genomic stability and response to nucleolar stress. NPM1 mutations are the most common genetic alteration in acute myeloid leukemia (AML), detected in about...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dactinomycin
Share to Histones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Proto-Oncogene Proteins c-bcl-2

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 36008542
DOI: 10.1038/s41375-022-01666-2
PMCID: PMC9522592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current status and future perspectives in targeted therapy of NPM1-mutated AML.PMID 36008542Read ↗

NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment StrategiesSemantic proximity Read ↗

NPM1-mutated acute myeloid leukemia: from bench to bedside.Semantic proximity Read ↗

NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.Semantic proximity Read ↗

Recent advances in AML with mutated NPM1.Semantic proximity Read ↗

Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.Semantic proximity Read ↗

NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.Semantic proximity Read ↗

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation.Semantic proximity Read ↗

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?Semantic proximity Read ↗

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemiaSemantic proximity Read ↗

Targeted therapy in NPM1-mutated AML: Knowns and unknownsSemantic proximity Read ↗

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.Semantic proximity Read ↗

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.